Accelerate Diagnostics, Inc. Sustainability Profile
Accelerate Diagnostics, Inc., commonly referred to as Accelerate, is a leading innovator in the field of diagnostic solutions, headquartered in the United States. Founded in 2012, the company has rapidly established itself within the medical diagnostics industry, focusing primarily on the development of advanced technologies for the rapid detection of infectious diseases. With a strong presence in major operational regions across North America and Europe, Accelerate's core products, including the Accelerate Pheno™ system, stand out for their ability to deliver precise results in a fraction of the time compared to traditional methods. This unique capability not only enhances patient care but also optimises antibiotic stewardship. Recognised for its commitment to improving clinical outcomes, Accelerate Diagnostics has achieved significant milestones, positioning itself as a key player in the market for rapid diagnostic solutions.
DitchCarbon Score
How does Accelerate Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Accelerate Diagnostics, Inc.'s score of 17 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Accelerate Diagnostics, Inc.'s reported carbon emissions
As of the latest available data, Accelerate Diagnostics, Inc. does not report any specific carbon emissions figures, indicating a lack of publicly disclosed emissions data. Consequently, there are no recorded Scope 1, 2, or 3 emissions figures to analyse. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. This absence of data suggests that Accelerate Diagnostics, Inc. may not currently have a formalised strategy for addressing carbon emissions or climate change. In the context of the industry, it is increasingly important for companies to engage in transparent reporting and set ambitious climate targets to align with global sustainability goals. Without specific commitments or emissions data, Accelerate Diagnostics, Inc. may face challenges in demonstrating its environmental responsibility and commitment to reducing its carbon footprint.
How Carbon Intensive is Accelerate Diagnostics, Inc.'s Industry?
How Carbon Intensive is Accelerate Diagnostics, Inc.'s Location?
Accelerate Diagnostics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Accelerate Diagnostics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
